Serotonin Link to Heart Valves Found in Columbia Study

Surprising Ties Between Mood Meds and Mitral Valves

Picture a vital gate inside your heart that suddenly warps and lets precious blood slip backward, quietly raising pressure on your lungs and leaving you short of breath. Columbia University researchers have uncovered evidence that reduced activity of the serotonin transporter may speed up this damage in valves already affected by degenerative mitral regurgitation. Their multicenter work, published in Science Translational Medicine and supported by later studies, suggests a simple genetic test could one day help doctors personalize care for patients facing this common heart valve problem. The findings bring reassurance that everyday treatments remain safe for most people while highlighting new ways to protect those already at risk.

What is DMR?

Degenerative mitral regurgitation, or DMR, ranks among the most frequent forms of heart valve disease. The mitral valve sits between the left atrium and left ventricle, acting like a one-way gate that opens to let oxygen-rich blood flow forward and closes tightly to prevent any backward leak. In DMR the thin leaflets of this gate thicken, stretch, or lose their proper shape, so they no longer meet neatly. Blood then slips back into the left atrium, raising pressure toward the lungs and reducing the amount of oxygenated blood the body receives with each beat. Over years this extra strain can contribute to atrial fibrillation or heart failure. While medicines can ease symptoms such as fatigue and shortness of breath, they cannot reverse the underlying degeneration of the valve tissue itself. Understanding this mechanical failure helps explain why researchers are now exploring factors that might accelerate the process once it has begun.

The Serotonin Connection

Serotonin does far more than influence mood; it also circulates in the bloodstream and interacts with heart valve cells. The serotonin transporter, often called SERT, normally acts like a vacuum cleaner that quickly removes excess serotonin from the space around cells, keeping levels balanced. Selective serotonin reuptake inhibitors, or SSRIs, work by blocking this transporter so more serotonin remains available in the brain, which helps many people manage depression and anxiety. In valve tissue, however, lower SERT activity can leave serotonin lingering longer near the cells. This prolonged exposure appears to encourage fibroblasts to produce extra collagen, gradually making leaflets thicker and stiffer. The Columbia-led team emphasized that healthy valves seem able to tolerate these changes without harm, yet valves already showing early degenerative signs may respond differently. This distinction forms the reassuring core of their message to patients and clinicians alike.

What the Data Showed

The investigators reviewed clinical records from more than 9,000 patients who underwent mitral valve surgery for DMR and examined 100 mitral valve biopsies obtained during those operations. Patients taking SSRIs tended to reach the point of severe regurgitation and need surgery at a younger age than those not taking the medications. Because the study was observational, it cannot prove that SSRIs directly cause faster progression; it only shows an association that warrants further attention. The biopsy samples revealed measurable differences in tissue structure and cellular behavior linked to serotonin signaling. These large numbers give the findings real weight while reminding everyone that individual results vary widely. Doctors continue to view SSRIs as generally safe and beneficial for the vast majority of patients who need them.

The Genetic Piece

Within the SERT gene lies a region called 5-HTTLPR that helps control how much transporter protein the body produces. A “long” variant of this region is associated with lower transporter activity, meaning serotonin lingers longer around valve cells. Patients who carried two copies of this long variant, known as the long-long genotype, underwent surgery for DMR more frequently than others. In laboratory tests, cells from these individuals reacted more vigorously to serotonin and generated higher amounts of collagen, leading to thicker, less flexible valve tissue. The researchers propose that a simple blood test or cheek swab could identify this genetic pattern in people already diagnosed with DMR. Such information might help doctors monitor certain patients more closely without changing medications that are otherwise helpful. This genetic insight adds a layer of personalization to future care plans.

Later Studies (2024-2025)

Building on the original 2023 findings, a 2024 mouse study showed that animals with reduced SERT activity developed greater fibrotic changes not only in heart valves but also in the surrounding heart muscle. These results strengthened the idea that lower transporter function can amplify scarring once degeneration has started. In 2025 another investigation turned attention to aortic stenosis, exploring whether similar serotonin-related mechanisms might influence other heart valves. Together the studies paint a consistent picture: serotonin signaling matters most when valve tissue is already vulnerable. The Columbia team and their partners at Children’s Hospital of Philadelphia, the University of Pennsylvania, and the Valley Hospital Heart Institute continue to track these pathways. Their collaborative approach keeps the focus on practical steps that could improve outcomes for patients.

What This Means for Patients

The researchers suggest that people living with DMR could one day receive a quick DNA test to check their 5-HTTLPR status and guide monitoring frequency. Giovanni Ferrari, PhD, the study’s co-leader, offered clear reassurance: “A healthy mitral valve can probably stand low SERT activity without deforming. It is unlikely that low SERT can cause degeneration by itself. SSRIs are generally safe for most patients. Once the valve has started to degenerate, it may be more susceptible.” Patients should continue taking prescribed medications unless their own doctor recommends changes. Regular check-ups with a cardiologist remain the best way to track valve function, and any new symptoms such as increasing fatigue or palpitations deserve prompt attention. This growing body of evidence empowers patients and physicians to work together on thoughtful, individualized plans that balance mental and heart health.